What is the Purpose of this Study?
This study focuses on people who have been diagnosed with progressive supranuclear palsy (PSP) or have a probable diagnosis of PSP. PSP is a nervous system disease that affects nerve cells in the brain and spinal cord; it worsens over time, causing loss of muscle control and neurological issues. The purpose of this study is to determine the safety and effectiveness of an experimental drug called AMX0035 for the treatment of PSP. Researchers also want to learn whether AMX0035 can slow down disease progression. AMX0035 is an oral medication (taken by mouth).
Eligibility
- * Male or female 40 to 80 years of age, inclusive
- * Diagnosis of possible or probable PSP Richardson Syndrome
- * Presence of PSP symptoms for \<5 years
- * Score of \<40 on the total (28-item) Progressive Supranuclear Palsy Rating Scale (PSPRS)
- * Male or female 40 to 80 years of age, inclusive
- * Diagnosis of possible or probable PSP Richardson Syndrome
- * Presence of PSP symptoms for \<5 years
- * Score of \<40 on the total (28-item) Progressive Supranuclear Palsy Rating Scale (PSPRS)
- * Able to walk independently or with minimal assistance
- * Minimum score of 24 on the Mini Mental State Examination (MMSE)
- * Must reside outside a skilled nursing facility or dementia care facility at the time of screening. Residence in an assisted living facility is allowed
- * Must have a study partner willing to attend study visits and provide information on participant's status
- * Capable of providing informed consent
- * Capable and willing to comply with trial procedures including visits to the trial clinic, visit requirements and treatment schedule, including MRI scans
- * Female participants of childbearing potential must agree to use effective birth control for the duration of the study and for 6 months after last dose of study drug.
- * Males must agree to use effective birth control method for the duration of the study and for 6 months after the last dose of study drug. Men must not plan to donate sperm.
- * Require use of a feeding tube
- * Evidence of any neurological disorder that could explain signs of PSP
- * Evidence of any clinically significant neurological disorder other than PSP, including significant cerebrovascular abnormalities, vascular dementia, motor neuron disease or ALS, Huntington's disease, normal pressure hydrocephalus, brain tumor, seizure disorder, multiple sclerosis, or known structural brain abnormalities.
- * History of autosomal dominant PSP due to a Microtubule Associated Protein Tau (MAPT) mutation
- * History of an autosomal dominant mutation associated with Frontotemporal Lobar Degeneration (FTLD)
- * Prior or current diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder
- * Presence of unstable psychiatric disease, cognitive impairment (e.g., major cognitive dysfunction), dementia, major depression, or substance abuse that would impair ability of the participant to provide informed consent and follow instructions
- * Abnormal liver function
- * Renal insufficiency
- * Ongoing anemia
- * History of Class III/IV heart failure per New York Heart Association (NYHA)
Inclusion Criteria:
Exclusion Criteria:
Where can I participate?
Beverly
More about this Clinical Trial
What is the full name of this clinical trial?
A Phase 3 Study of Safety and Efficacy of AMX0035 in Progressive Supranuclear Palsy
Study Details
Disease Type/Condition
Movement Disorders
Principal Investigator
INVALID PROFILE1<!DOCTYPE html>
<!-- image: web-v6.21.0.3 -->
<!-- hash: 10ec7068e3ff585b0a19a2c8ecfee4885e27412b -->
<!-- Inter font is copyright (c) 2016 The Inter Project Authors (https://github.com/rsms/inter), included under the SIL license: https://openfontlicense.org/documents/OFL.txt. -->
<!-- Barlow Condensed font is copyright 2017 The Barlow Project Authors (https://github.com/jpt/barlow), included under the SIL license: https://openfontlicense.org/documents/OFL.txt. -->
<!-- Poppins font is copyright 2014-2019 Indian Type Foundry (info@indiantypefoundry.com), included under the SIL license: https://openfontlicense.org/documents/OFL.txt. -->
<!-- Montserrat font is copyright 2011 The Montserrat Project Authors (https://github.com/JulietaUla/Montserrat), included under the SIL license: https://openfontlicense.org/documents/OFL.txt. -->
<!-- blue -->
<html lang="en">
<head>
<meta http-equiv="X-UA-Compatible" content="IE=edge" />
<meta charSet="UTF-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0" />
<meta name="theme-color" content="#ffffff" />
<title>Discovery</title>
<link href='/css/app.css' rel='stylesheet' type='text/css' />
<link rel="icon" type="image/x-icon" href="data:image/x-icon;base64,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">
</head>
<body style="--logoHeight:55px;--logoVerticalMargins:7px;--homeBackgroundDesktopOverlayOpacity:0.54;--homeBackgroundDesktopUrl:url(/branding/homeBackgroundDesktop);--homeBackgroundMobileUrl:url(/branding/homeBackgroundMobile);--searchBackgroundUrl:url(/branding/searchBackground);--colourPrimary:#bb1a0d;--colourPrimaryPair1Background:#f8e8e7;--colourPrimaryPair1Foreground:#9f160b;--colourPrimaryPair2Background:#f3d8d6;--colourPrimaryPair2Foreground:#8c140a;--colourSecondary:#bb1a0d;--colourSecondaryPair1Background:#f8e8e7;--colourSecondaryPair1Foreground:#9f160b;--colourSecondaryPair2Background:#f3d8d6;--colourSecondaryPair2Foreground:#8c140a;" class=darkMode id="portalTarget">
<div id="app"></div>
<script src="/javascript/configuration.js"></script>
<script src="/javascript/client.js"></script>
</body>
</html>
Age Group
Adult
Phase
III
IRB Number
STUDY00003182
ClinicalTrials.gov ID
NCT06122662
Key Eligibility
ClinicalTrials.gov How do I learn more about this study?
Email
clinicaltrials@cshs.org